Format

Send to

Choose Destination
Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Author information

1
Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, P Vall d'Hebron 119-129, Barcelona 08035, Spain.
2
Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Avda Blasco Ibáñez 17, Valencia 46010, Spain.
3
Department of Gastroenterology, University Hospitals Gasthuisberg and KU Leuven, Herestraat 49, Leuven 3000, Belgium.
4
Department of Experimental and Clinical Medicine, Second University of Naples, Via S Pansini 5, Naples 80131, Italy.
5
Merck Serono SA, 9 Chemin des Mines, Geneva 1202, Switzerland.
6
Merck KGaA, Frankfurter Strasse 250, F131/102, Darmstadt 64293, Germany.

Abstract

BACKGROUND:

The mitogen-activated protein kinase (MAPK) pathway has been implicated in the molecular pathogenesis of human cancers, including metastatic colorectal cancer (mCRC). This provides a rationale for the development of MAPK-targeted agents such as pimasertib.

METHODS:

Patients with KRAS mutant mCRC were treated in the second-line setting with FOLFIRI (5-fluorouracil/folinic acid/irinotecan) plus pimasertib. The primary objective of the safety run-in phase was to determine the maximum-tolerated dose (MTD) and the recommended phase II dose of pimasertib combined with FOLFIRI.

RESULTS:

Sixteen patients were enrolled in the trial. Ten and six patients were treated daily with 45 and 60 mg of pimasertib plus FOLFIRI, respectively. The MTD was considered to be 45 mg per day. The most common treatment-emergent adverse events were diarrhoea, nausea, vomiting, asthenia and skin/rash event. Of the 15 patients in the efficacy analysis group, two patients had partial response, nine patients had stable disease, three patients had progressive disease as their best overall response and one patient could not be evaluated.

CONCLUSIONS:

Dose escalation of pimasertib in combination with FOLFIRI was limited by toxicity. At the MTD of 45 mg per day, pimasertib was adequately tolerated in patients with mCRC and no unexpected or new safety signals or concerns were identified.

PMID:
25989270
PMCID:
PMC4580393
DOI:
10.1038/bjc.2015.144
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center